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Effect of Enzyme Induction on
Nephrotoxicity of Halothane-Related
Compounds
by Ben A. Hitt* and Richard 1. Mazzet
Nephrotoxicity following administration of methoxyflurane has been shown to be directly related to
anesthetic metabolism to inorganic fluoride. Enzyme induction should increase metabolic rate and the
amount of inorganic fluoride that is released. In vivo studies in Fischer 344 rats show that enzyme
induction with phenobarbital or phenytoin increases defluorination following methoxyflurane anesthesia
but not after enflurane or isoflurane. In vitro, methoxyflurane defluorinase activity was increased far
more than that of any of the other anesthetics. These data suggest that treatment with enzyme inducing
drugs increases the risk of nephrotoxicity only if methoxyflurane is the anesthetic agent.
For purposes of this discussion, the potent,
fluorinated, inhalational anesthetics are considered
halothane-related compounds. They differ from
halothane in that they are aliphatic ethers which
when biotransformed liberate inorganic fluoride.
Halothane is a fluorinated ethane which, except
under conditions of extreme hypoxia, does not
breakdown to inorganic fluoride (1). Since post-
anesthetic nephrotoxicity is directly related to inor-
ganic fluoride concentration in the serum,
halothane should not be considered a nephrotoxin.
Nephrotoxicity associated with anesthetic ad-
ministration was first reported by Crandell et al. (2)
in a study of patients anesthetized with methoxy-
flurane (CHC12-CF2-0-CH). Thirteen of 41
patients had polyuria with negative fluid balance,
increased serum sodium and blood urea nitrogen
concentrations and fixed urinary osmolality, close
to that ofserum. Polyuria was resistant to fluid dep-
rivation and vasopressin administration. These
findings were later confirmed in both man and ani-
mals (3, 4). Besides methoxyflurane, only enflurane
(CHClF-CF2-0-CF2H) administration has re-
sulted in decreased urinary concentrating ability.
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This review will discuss the relationship of anes-
thetic metabolism and enzyme induction to inor-
ganic fluoride nephrotoxicity.
Evidence Relating Anesthetic
Metabolism to Nephrotoxicity
Until the reports of Van Dyke et al. (5, 6) de-
scribing the biotransformation of diethyl ether,
chloroform, and halothane, it was thought that inha-
lational anesthetics were pharmacologically active
but metabolically inert chemicals. It is now known
that all of the volatile inhalational anesthetics are
metabolized. The relationship between anesthetic
metabolism and nephrotoxicity was first suggested
when increased concentrations of inorganic
fluoride, a metabolite of methoxyflurane were
noted in the serum and urine of a patient with renal
dysfunction following methoxyflurane anesthesia
(7).
Mazze and associates (8, 9) subsequently related
serum inorganic fluoride concentration, methoxy-
flurane exposure in MAC-hours and the degree of
nephrotoxicity. (MAC is defined as the minimum
alveolar concentration of anesthetic required to
prevent movement in response to skin incision in
50% of patients. MAC-hours is the product of
anesthetic concentration expressed in units of
MAC and time expressed in hours.) A clear dose-
response relationship was seen. The earliest signs
December 1977 179of nephrotoxicity occurred at inorganic fluoride
levels of50 tM with clinical nephrotoxicity evident
at concentrations of 80-175 lM.
There have been additional studies of urinary
concentrating ability following anesthesia with
other fluorinated agents. Metabolism of isoflurane
(CF:-CHC1-O-CF2H) has been demonstrated,
but this occurs to a very small extent (10). In man,
mean peak serum inorganic fluoride level following
operations lasting an average of4.1 hr was 4.4 ,tM;
a concentrating defect was not observed. Enflurane
anesthesia averaging 2.7 MAC-hr resulted in a
mean peak inorganic fluoride level of 22 gM (11).
There was no difference in concentrating ability in
this study among patients anesthetized with en-
flurane and with halothane, the control anesthetic
agent. However volunteers anesthetized with en-
flurane for 9.6 MAC-hr had mean peak inorganic
fluoride levels of 34 gM. They had a 26% decrease
in preanesthetic concentrating ability during the
first 24 hr following anesthesia (12). This impair-
ment was transient and probably would be clinically
insignificant in patients with normal preanesthetic
renal function.
Figure I correlates peak serum inorganic fluoride
level following halothane, enflurane, and methoxy-
flurane anesthesia with decreased urinary osmolal-
ity as measured by the response to vasopressin ad-
ministration; data are from the studies referred to
above. The positive correlation between impaired
urinary concentrating ability and serum inorganic
fluoride level following administration of different
anesthetics is strong evidence that anesthetic ne-
phrotoxicity in man is due to metabolic liberation of
inorganic fluoride.
Studies employing Fischer 344 rats have pro-
vided further evidence relating anesthetic
metabolism to nephrotoxicity. Mazze et al. (4) re-
ported vasopressin-resistant polyuric renal insuffi-
ciency following either anesthesia with methoxy-
flurane or injection of inorganic fluoride. Cousins
et al. (13) showed that phenobarbital treatment of
Fischer 344 rats prior to methoxyflurane anesthesia
resulted in higher serum inorganic fluoride levels
and more severe nephrotoxicity than in control
animals (Fig. 2). Conversely, administration of
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FIGURE 1. Individual changes in urinary osmolality following
enflurane, halothane and methoxyflurane anesthesia plotted
against peak serum inorganic fluoride levels. As peak serum
inorganic fluoride level increased, the ability to concentrate
urine decreased (r = 0.90). From Mazze et al. (12), repro-
duced with permission ofAnesthesiology.
FIGURE 2. Changes in serum inorganic fluoride (F-) concentra-
tion and urine volume for the first 2 days afteranesthesia (day
15): (C) control, group I; (Pb) phenobarbital, 25 mg/kg, b.i.d.,
days 11 to 14, group II; (MF) phenobarbital preceding
methoxyflurane, group IV; (A) days 7 to 10 minus days 16 to
17, mean + S.E. From Cousins et al. (13), reproduced with
permission of JoiurnIal of Pharmacology and Experimental
Therazpeuttics.
SKF 525A, an inhibitor of drug metabolizing en-
zymes resulted in lower serum inorganic fluoride
concentrations and less nephrotoxicity (Fig. 3).
They also showed that inorganic fluoride was the
principal nephrotoxic metabolite rather than oxalic
acid, the organic end product of methoxyflurane
metabolism. Oxalic acid administration resulted in
nephrotoxicity only when injected in quantities
10-fold greater than the amount excreted following
a nephrotoxic exposure to methoxyflurane; at that,
oxalic acid induced nephrotoxicity was of an
oliguric rather than a polyuric nature (Fig. 4). Addi-
tionally, Barr et al. (14) reported that 6 hr of en-
flurane exposure resulted in vasopressin resistant
Environmental Health Perspectives
.
_Ir140
Urine Volume M
Serum F-
C SKF
I
+
MF SKF-MF
-120
40- *100
80 k
IL
E
*60 a
40
V
E
E
.5 a
0
30-
20-
10-
20
Fluoride Injection
* 200 pmol NaF
o 100 pmol NaF
* 30,umol NaF
o 15.5 ,umol NaCI
I + S.E.
Pre- 1
Treatment
Oxalic Acid Injection
* 444 jjmol OA
o 222 ymol OA
* 44 pmol OA
o No Treatment
I ± S.E.
* P' 0.01 (MF vs. SKF-MF)
FIGURE 3. Changes in serum inorganic fluoride (F-) concentra-
tion and urine volume for the first 2 days after anesthesia (day
11): (C) control, group 1, SKF 525-A, 50 mg/kg, group II;
(MF) methoxyflurane, group IV; (A) days 7 to 10 minus days
12 to 13, mean + S.E. From Cousins et al. (13), reproduced
with permission of the Journal of Pharmacology and Ex-
perimental Therapeutics.
polyuria with serum inorganic fluoride concentra-
tion of 57 ,uM; a level similar to that seen during
methoxyflurane induced polyuria. Since the only
common metabolite of methoxyflurane and en-
flurane is inorganic fluoride, these data strongly
support the concept that inorganic fluoride, present
as a result of anesthetic biodegradation, is ne-
phrotoxic.
Enzyme Induction as a Factor
in Anesthetic Nephropathy
It is established that volatile anesthetics are
metabolized by the same microsomal enzyme sys-
tem which catalyzes the biodegradation of other
drugs. Cytochrome P450, the terminal oxidase in
the system, is induced by many compounds to
which surgical patients are exposed. If the activity
of enzymes which defluorinate volatile anesthetics
is increased, the risk of anesthetic nephropathy
should also be increased. In fact, Cousins et al. (14)
demonstrated that inorganic fluoride levels were
higher and nephrotoxicity more severe in enzyme
induced rats than in control rats simultaneously ex-
Days
FIGURE 4. Daily urine volume (mean + S.E.) before and after
treatment with oxalic acid (OA) and sodium fluoride (NaF).
Dose-related polyuria occurred after NaF injection but not
after OA. Treatment with 44 ,umole ofoxalic acid resulted in
oliguria. From Cousins et al. (13), reproduced with permis-
sion of the Journal of Pharmacology and Experimental
Therapeutics.
posed to methoxyflurane. Therefore, it is important
to determine if defluorination of other volatile
anesthetics might be increased thereby increasing
their nephrotoxic potential.
Mazze et al. (15) compared the effects of
phenobarbital treatment on the metabolism and
nephrotoxicity of methoxyflurane and isoflurane in
viv'o and in vitro in Fischer 344 rats. Phenobarbital
treatment prior to methoxyflurane exposure re-
sulted in higher serum inorganic fluoride concentra-
tion and greater nephrotoxicity. The same treat-
ment preceding isoflurane anesthesia did not in-
crease either serum inorganic fluoride concentra-
tion or urinary fluoride excretion. Thus, enzyme
induction does not significantly alter isoflurane
metabolism in vivo and does not increase its already
very low nephrotoxic potential. In contrast to this
were the results of in vitro studies. Specific ac-
tivities of both methoxyflurane (MOF) and iso-
flurane (ISO) defluorinating enzymes were greater
in microsomes prepared from the livers of
phenobarbital treated animals than in those pre-
pared from untreated animals (Table 1). Phenobar-
bital treatment increased methoxyflurane defluori-
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181Table 1. Anesthetic defluorination in vitro.
Defluorination,
,umole/F-30 min/mg protein
ISO ENF SEVO MOE
Noninduced
Xa 0.51 1.31 1.82 2.00
S.E. 0.09 0.23 0.30 0.11
Induced
Xa 1.51 1.63 3.22 18.89
S.E. 0.25 0.15 0.46 2.40
I/N
Xa 3.60b 1.35 1l90b 9.75b
S.E. 0.80 0.15 0.25 1.50
aMean + S.E., n = 9.
bp<0. IIN # 1.
nation by 9.75-fold and isoflurane by 3.6-fold. In
light of this finding, the inability to demonstrate an
increase in isoflurane metabolism in vivo can not be
fully explained. It was suggested that the low solu-
bility of isoflurane in fat (oil/gas = 98), relative to
methoxyflurane (oil/gas = 930), led to its rapid pul-
monary excretion; thus, substrate (isoflurane)
availability rather than enzyme availability was rate
limiting in vivo, masking the effect of enzyme in-
duction.
In vivo studies with enflurane (ENF) supported
this concept, as phenobarbital treatment neither in-
creased metabolism of the relatively insoluble
anesthetic (oil/gas = 98) nor the nephrotoxic re-
sponse to its administration. In vitro findings were
surprising, in that enflurane defluorination was not
increased by phenobarbital treatment (Table 1). A
study of the effects of phenobarbital treatment on
the metabolism and nephrotoxicity of sevoflurane
[(CF3)2-CH-0--CH2F; oil/gas = 55] however,
suggested that substrate availability was not the
rate-limiting factor governing its in vivo de-
fluorination (16). Phenobarbital-treated rats had a
100% increase in urinary fluoride excretion as com-
pared to nonphenobarbital treated controls. In vitro
microsomes prepared from phenobarbital treated
rats defluorinated sevoflurane (SEVO) 1.9 times
more than microsomes prepared from control rats.
Sevoflurane is the least soluble ofthe volatile inha-
lational anesthetics; if substrate availability were
rate limiting, its metabolism in vivo should not have
been increased by phenobarbital treatment.
Effect of Other Inducing Agents
Most research on the induction ofenzymes which
defluorinate the volatile anesthetics has been per-
formed using phenobarbital as the inducing agent.
The rationale for this method ofprocedure has been
that all volatile anesthetics belong to the same class
of substrates and, presumably, are metabolized by
the same enzyme (17). If this were correct, induc-
tion of defluorination of different anesthetics by
phenobarbital should have been uniform. Data in
Table I indicate that this is not the case. Therefore,
we have begun to examine the effects of other in-
ducing agents on the defluorination of the volatile
anesthetics. Preliminary data suggest that
3-methylcholanthrene has no effect on methoxy-
flurane metabolism and nephrotoxicity, whereas
phenytoin was found to have nearly the same effect
as phenobarbital, both in vivo and in vitro (18).
Effect of Enzyme-inducing
Agents on Anesthetic
Nephrotoxicity in Humans
There are no data in humans relating drug treat-
ment and anesthetic defluorination. However,
studies of anesthetic metabolism have demon-
strated large variations in the amount ofdefluorina-
tion among individuals which could be due to en-
zyme induction (3, 8-12). In one study, Cousins
et al. (11) reported a patient with a peak serum in-
organic fluoride concentration of 106 ,uM following
enflurane anesthesia, considerably greater than the
mean volume of 22 AM measured in the remaining
patients. This patient was on a multiple drug treat-
ment program and it was felt that his enzymes may
have been induced. These suggestions of enzyme
induction in surgical patients clearly indicate the
need for further clinical investigations. At the pres-
ent time, however, we can only speculate as to the
effects of treatment with enzyme inducing drugs on
the metabolism and nephropathy of the fluorinated
anesthetics. Based on animal data, we would pre-
dict the following: methoxyflurane should be more
nephrotoxic in enzyme-induced patients; it is un-
likely that enflurane metabolism can be significantly
induced so that its nephrotoxicity should be unre-
lated to drug treatment history; isoflurane and
sevoflurane metabolism may be increased by en-
zyme induction, however, inorganic fluoride levels
still should be well below the nephrotoxic threshold
of 35-50 ,uM; and halothane defluorination ordinar-
ily should not be increased by enzyme induction, so
that it will not be nephrotoxic in clinical practice.
This study was supported, in part, by the Veterans Adminis-
stration Hospital, Palo Alto, and National Institute of Health
Grant GM 22746.
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